Frakturrisikoevaluation mithilfe verschiedener nationaler und internationaler Risikoscores bei Frauen

Giessel, Anna

dc.contributor.advisor	Siggelkow, Heide Prof. Dr.
dc.contributor.author	Giessel, Anna
dc.date.accessioned	2021-11-02T13:57:00Z
dc.date.available	2021-11-27T00:50:03Z
dc.date.issued	2021-11-02
dc.identifier.uri	http://hdl.handle.net/21.11130/00-1735-0000-0008-5960-8
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-8903
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-8903
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc	610	de
dc.title	Frakturrisikoevaluation mithilfe verschiedener nationaler und internationaler Risikoscores bei Frauen	de
dc.type	doctoralThesis	de
dc.title.translated	National and international osteoporosis fracture evaluation in women	de
dc.contributor.referee	Siggelkow, Heide Prof. Dr.
dc.date.examination	2021-11-17
dc.description.abstracteng	In the management of osteoporosis the determination of fracture risk is essential for the indication of a specific antiosteoporotic treatment. Within Europe different scores are used for fracture risk prediction. We used the German Guidelines of the Dachverband Osteologie (DVO) and FRAX in the version for Germany as well as not established scores (FRAXendo, DVO+) and compared fracture risks in relation to the actual treatment indication in Germany in women evaluated for osteoporosis. In this retrospective study 555 female patients presenting to the MVZ endokrinologikum Goettingen between July 2007 and June 2014 for evaluation of osteoporosis were investigated. Patient files were analysed for DVO-based 10-year fracture probabilities and for data for the calculation of FRAX-score for major osteoporotic fracture (MOF) and hip fracture (HF). We calculated the DVO Guideline risk score which recommended a specific antiosteoporotic therapy exceeding a 10-year fracture risk of > 30 % and compared the identified patients with those identified by different published thresholds for the FRAX-score (MOF ≥ 14 % resp. ≥ 20 % and HF ≥ 3 %). The study revealed that we treated different women using DVO score and published thresholds for FRAX. Nonetheless in direct comparison there is no significant difference between patients with therapy indication following DVO and FRAX therapy threshold HF ≥ 3 %. In follow up studies the number of incident fractures has to be investigated to evaluate the validity of the different scores for Germany.	de
dc.contributor.coReferee	Hoffmann, Daniel PD Dr.
dc.contributor.thirdReferee	Schön, Margarete Prof. Dr.
dc.subject.eng	osteoporosis	de
dc.subject.eng	bone mineral density	de
dc.subject.eng	fracture risk	de
dc.subject.eng	FRAX	de
dc.subject.eng	DVO	de
dc.subject.eng	DXA	de
dc.identifier.urn	urn:nbn:de:gbv:7-21.11130/00-1735-0000-0008-5960-8-1
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	GOK-MEDIZIN	de
dc.description.embargoed	2021-11-27
dc.identifier.ppn	1775948390

Dateien

Name:eDiss_Frakturrisikoevaluation mithilfe verschiedener nationaler und internationaler Risikoscores bei Frauen_AGiessel_2021.pdf

Größe:1.864Mb

Format:PDF

Beschreibung:Dissertation

Öffnen

Name:: eDiss_Frakturrisikoevaluation ...
Größe:: 1.864Mb
Format:: PDF
Beschreibung:: Dissertation

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2873]

Zur Kurzanzeige